UK markets close in 2 hours 11 minutes
  • FTSE 100

    7,048.85
    +140.09 (+2.03%)
     
  • FTSE 250

    17,729.06
    +444.18 (+2.57%)
     
  • AIM

    815.48
    +6.75 (+0.83%)
     
  • GBP/EUR

    1.1454
    -0.0062 (-0.54%)
     
  • GBP/USD

    1.1361
    +0.0042 (+0.37%)
     
  • BTC-GBP

    17,597.63
    +526.68 (+3.09%)
     
  • CMC Crypto 200

    454.32
    +18.96 (+4.36%)
     
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • DOW

    29,490.89
    +765.38 (+2.66%)
     
  • CRUDE OIL

    85.61
    +1.98 (+2.37%)
     
  • GOLD FUTURES

    1,720.90
    +18.90 (+1.11%)
     
  • NIKKEI 225

    26,992.21
    +776.42 (+2.96%)
     
  • HANG SENG

    17,079.51
    -143.32 (-0.83%)
     
  • DAX

    12,561.22
    +351.74 (+2.88%)
     
  • CAC 40

    5,990.17
    +196.02 (+3.38%)
     

Silence Therapeutics to Present at Jefferies Healthcare Conference

·1-min read

LONDON, June 02, 2022--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. EDT / 2:00 p.m. GMT.

A live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005054/en/

Contacts

Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208